Aktieanalys

Vicore Pharma: Short comment on new ATRAG “C103” - Redeye

Redeye 13 Oct 2022 08:43

Redeye remains impressed by the rapid development of Vicore’s new generation of ATRAGs (angiotensin II type 2 receptor agonists) in its VP03 program, including yesterday’s announcement of new drug candidate, C103. As stated in the release, it has a very high affinity to the AT2 receptor compared to the AT1 receptor, making it especially suitable for indications such as preeclampsia. The company will now initiate a toxicology program with the hope to take C103 into the clinic by H2 2023. We continue to see the phase II study with C21 in IPF as the most critical catalyst for the share price in the short to mid-term, but we will likely dig deeper into the VP03 program once we have a better sense of target indications.

Länk till analysen i sin helhet: https://www.redeye.se/research/857928/vicore-pharma-short-comment-on-new-atrag-c103?utm_source=finwire&utm_medium=RSS

Börskollens app – Högt betyg ⭐⭐⭐⭐⭐ och 250.000 nedladdningar

Ladda hem

Vårt nyhetsbrev – Utvalda börsnyheter och heta investeringscase varje vecka

Prenumerera

Nyheter om Vicore Pharma

Läses av andra just nu

Innehåller annonslänkar. Investeringar innebär risk (se här)

Tips: 50% rabatt hos fondroboten Opti

Dags att komma igång med sparande? Fondroboten Opti erbjuder en populär spartjänst som är perfekt för regelbundet månadssparande. Just nu får nya kunder som använder Börskollens unika kampanjkod BORSKOLLEN50 automatiskt 50 % rabatt på Optis avgift i 3 månader!